ERBB2 and breast carcinoma: ExoCAR/T7@Micelle crossed the blood-brain barrier, selectively targeted HER2+ breast cancer cells, and enhanced therapeutic efficacy by disrupting ferroptosis defense through drug delivery [93] (Figure 3C).